280 related articles for article (PubMed ID: 8687048)
1. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
[TBL] [Abstract][Full Text] [Related]
2. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
[No Abstract] [Full Text] [Related]
3. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
4. Fotemustine for the treatment of melanoma.
Quéreux G; Dréno B
Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
[TBL] [Abstract][Full Text] [Related]
5. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
Célérier P; Dreno B; Bureau B; Litoux P
Ann Dermatol Venereol; 1993; 120(6-7):437-40. PubMed ID: 8279787
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
Gill S; Shapiro J; Westerman D; Prince HM
J Clin Oncol; 2007 Oct; 25(28):4493-4. PubMed ID: 17906211
[No Abstract] [Full Text] [Related]
7. Persistent thrombocytopenia during melanoma treatment with fotemustine.
Turrisi G; Sozzi P; Marinozzi C; Clerico MA
Melanoma Res; 2006 Dec; 16(6):543-4. PubMed ID: 17119456
[TBL] [Abstract][Full Text] [Related]
8. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
9. [New toxicity of fotemustine: diffuse interstitial lung disease].
Bertrand M; Wémeau-Stervinou L; Gauthier S; Auffret M; Mortier L
Ann Dermatol Venereol; 2012 Apr; 139(4):277-81. PubMed ID: 22482481
[TBL] [Abstract][Full Text] [Related]
10. [Contribution of a new nitrosourea compound: fotemustine].
Boaziz C
Pathol Biol (Paris); 1992 Dec; 40(9 Pt 2):964-8. PubMed ID: 1338920
[TBL] [Abstract][Full Text] [Related]
11. Effective combined immunochemotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma.
Göring HD; Zierner A; Kröning Y; Trebing D; Kämpgen E; Bröcker EB
Melanoma Res; 1998 Aug; 8(4):379. PubMed ID: 9764815
[No Abstract] [Full Text] [Related]
12. Neurological toxicity during metastatic melanoma treatment with fotemustine.
Khalil Z; Pageot N; Carlander B; Guillot B
Melanoma Res; 2005 Dec; 15(6):563-4. PubMed ID: 16314745
[TBL] [Abstract][Full Text] [Related]
13. Fotemustine with or without dacarbazine for brain metastases of malignant melanoma.
Merimsky O; Inbar M; Reider-Groswasser I; Chaitchik S
Eur J Cancer; 1991; 27(8):1066. PubMed ID: 1832900
[No Abstract] [Full Text] [Related]
14. Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma.
Pontes L; Lopes M; Ribeiro M; Santos JG; Azevedo MC
Melanoma Res; 1997 Oct; 7(5):417-9. PubMed ID: 9429225
[TBL] [Abstract][Full Text] [Related]
15. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence.
Bonenkamp JJ; Thompson JF; de Wilt JH; Doubrovsky A; de Faria Lima R; Kam PC
Eur J Surg Oncol; 2004 Dec; 30(10):1107-12. PubMed ID: 15522559
[TBL] [Abstract][Full Text] [Related]
16. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
Khayat D; Avril MF; Gerard B; Bertrand P; Bizzari JP; Cour V
Melanoma Res; 1992 Sep; 2(3):147-51. PubMed ID: 1450667
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
18. [Fotemustine: muphoran].
Avril MF
Ann Dermatol Venereol; 2007 Dec; 134(12):997-1000. PubMed ID: 18166925
[No Abstract] [Full Text] [Related]
19. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
Schallreuter KU; Wenzel E; Brassow FW; Berger J; Breitbart EW; Teichmann W
Cancer Chemother Pharmacol; 1991; 29(1):85-7. PubMed ID: 1742855
[TBL] [Abstract][Full Text] [Related]
20. [Brain metastases of malignant melanomas].
Boaziz C; Breau JL; Morere JF; Israël L
Bull Cancer; 1991; 78(4):347-53. PubMed ID: 1859902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
